感染指南

订阅

MedSci主页 / 所有栏目 / 感染指南

2018 共识报告：免疫抑制治疗和乙型肝炎再激活风险

2018-05-04 外国肝病科相关专家小组（统称） Turk J Gastroenterol. 2018 May;29(3):259-269.

免疫抑制治疗乙型肝炎再激活风险

本文主要介绍了 因具有乙肝再次激活风险而接受免疫移植治疗的患者乙型肝炎筛查，随访，预防和治疗的专家观点和建议。全文共包括9个方面的内容，涉及乙肝的患病率，乙肝血清学检查，乙肝在活化的结局和意义，血清学状态和疾病复发风险，免疫抑制性疾病和复发风险，乙肝再激活的筛查，预防和治疗。

中文标题：

2018 共识报告：免疫抑制治疗和乙型肝炎再激活风险

英文标题：

Immunosuppressive therapy and the risk of hepatitis B reactivation: Consensus report.

发布机构：

外国肝病科相关专家小组（统称）

发布日期：

2018-05-04

简要介绍：

本文主要介绍了 因具有乙肝再次激活风险而接受免疫移植治疗的患者乙型肝炎筛查，随访，预防和治疗的专家观点和建议。全文共包括9个方面的内容，涉及乙肝的患病率，乙肝血清学检查，乙肝在活化的结局和意义，血清学状态和疾病复发风险，免疫抑制性疾病和复发风险，乙肝再激活的筛查，预防和治疗。 

拓展指南：与乙肝相关指南：

相关资料下载：
[AttachmentFileName(sort=100, fileName=2018 共识报告：免疫抑制治疗和乙型肝炎再激活风险)] GetToolGuiderByIdResponse(projectId=1, id=ec1ae1c001592887, title=2018 共识报告：免疫抑制治疗和乙型肝炎再激活风险, enTitle=Immunosuppressive therapy and the risk of hepatitis B reactivation: Consensus report., guiderFrom=Turk J Gastroenterol. 2018 May;29(3):259-269., authorId=null, author=, summary=本文主要介绍了 因具有乙肝再次激活风险而接受免疫移植治疗的患者乙型肝炎筛查，随访，预防和治疗的专家观点和建议。全文共包括9个方面的内容，涉及乙肝的患病率，乙肝血清学检查，乙肝在活化的结局和意义，血清学状态和疾病复发风险，免疫抑制性疾病和复发风险，乙肝再激活的筛查，预防和治疗。 , cover=, journalId=null, articlesId=null, associationId=687, associationName=外国肝病科相关专家小组（统称）, associationIntro=外国的关于肝病方面制定者的统称, copyright=0, guiderPublishedTime=Fri May 04 00:00:00 CST 2018, originalUrl=, linkOutUrl=, content=<div>本文主要介绍了 因具有乙肝再次激活风险而接受免疫移植治疗的患者乙型肝炎筛查，随访，预防和治疗的专家观点和建议。全文共包括9个方面的内容，涉及乙肝的患病率，乙肝血清学检查，乙肝在活化的结局和意义，血清学状态和疾病复发风险，免疫抑制性疾病和复发风险，乙肝再激活的筛查，预防和治疗。 </div> <div><br> </div> 拓展指南：<strong>与<font color=red>乙肝</font>相关指南：</strong><br><ul><li><a href="http://www.medsci.cn/guideline/show_article.do?id=89d781c001562eeb" title="2018 专家共识：亚裔美国人慢性乙肝的管理" target=_blank>2018 专家共识：亚裔美国人慢性乙肝的管理</a></li> <li><a href="http://www.medsci.cn/guideline/show_article.do?id=972d81c001523eaf" title="2017 ACP/CDC最佳实践建议：乙肝疫苗接种，筛查以及护理" target=_blank>2017 ACP/CDC最佳实践建议：乙肝疫苗接种，筛查以及护理</a></li> <li><a href="http://www.medsci.cn/guideline/show_article.do?id=7852e1c001a66ec8" title="2017 WHO意见书：乙肝疫苗" target=_blank>2017 WHO意见书：乙肝疫苗</a></li> <li><a href="http://www.medsci.cn/guideline/show_article.do?id=933441c001a658a2" title="2017 意见书：血液系统恶性肿瘤以及接受造血干细胞移植患者乙肝病毒再激活的筛查，监测预防以及治疗建议" target=_blank>2017 意见书：血液系统恶性肿瘤以及接受造血干细胞移植患者乙肝病毒再激活的筛查，监测预防以及治疗建议</a></li> <li><a href="http://www.medsci.cn/guideline/show_article.do?id=141cf1c0013192ff" title="2016 ACOG委员会意见：妇产科医师乙肝，丙肝和艾滋病毒感染（No.655）" target=_blank>2016 ACOG委员会意见：妇产科医师乙肝，丙肝和艾滋病毒感染（No.655）</a></li> 更多信息请点击：<a href="http://www.medsci.cn/guideline/list.do?q=%E4%B9%99%E8%82%9D" target=_blank>有关乙肝更多指南</a></ul>, tagList=[TagDto(tagId=12863, tagName=免疫抑制治疗), TagDto(tagId=75002, tagName=乙型肝炎再激活风险)], categoryList=[CategoryDto(categoryId=9, categoryName=感染, tenant=100), CategoryDto(categoryId=22, categoryName=肝病, tenant=100), CategoryDto(categoryId=21100, categoryName=达仁堂循证e学界, tenant=100)], articleKeywordId=null, articleKeyword=null, articleKeywordNum=null, guiderKeywordId=null, guiderKeyword=null, guiderKeywordNum=null, haveAttachments=1, attachmentList=null, guiderType=0, guiderArea=共识, guiderLanguage=0, guiderRegion=0, opened=0, paymentType=null, paymentAmount=10, recommend=0, recommendEndTime=null, sticky=0, stickyEndTime=null, allHits=5532, appHits=209, showAppHits=0, pcHits=4338, showPcHits=1535, likes=101, shares=6, comments=3, approvalStatus=1, publishedTime=Thu May 17 23:15:00 CST 2018, publishedTimeString=2018-05-04, pcVisible=1, appVisible=1, editorId=2020535, editor=qiushida2, waterMark=0, formatted=0, memberCards=[], isPrivilege=0, deleted=0, version=1, createdBy=null, createdName=qiushida2, createdTime=Thu May 17 23:15:00 CST 2018, updatedBy=null, updatedName=null, updatedTime=Tue Jan 02 10:59:42 CST 2024, courseDetails=[], otherVersionGuiders=[], isGuiderMember=false, ipAttribution=, attachmentFileNameList=[AttachmentFileName(sort=100, fileName=2018 共识报告：免疫抑制治疗和乙型肝炎再激活风险)])
2018 共识报告：免疫抑制治疗和乙型肝炎再激活风险
下载请点击：
评论区 (3)
#插入话题
  1. [GetPortalCommentsPageByObjectIdResponse(id=890958, encodeId=006b890958fd, content=我要下载, beContent=null, objectType=guider, channel=null, level=null, likeNumber=87, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=dc0c2071567, createdName=1871f037efm, createdTime=Sat Oct 10 09:23:20 CST 2020, time=2020-10-10, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=316352, encodeId=2aa831635298, content=好, beContent=null, objectType=guider, channel=null, level=null, likeNumber=100, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=41962298363, createdName=121ff658m46暂无昵称, createdTime=Fri May 18 15:42:59 CST 2018, time=2018-05-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=316134, encodeId=823531613478, content=谢谢分享学习, beContent=null, objectType=guider, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/Q3auHgzwzM4o2XVpJ6449yqDsjibydI5HnJ8MibGxNn4HZiaZib0bdfibbwoz3KQrIyN9AGxq36ZlZRNicYlPfOOWMtwgsajY6mGNFiaPclFdowjD0/0, createdBy=97bd1338592, createdName=清风拂面, createdTime=Thu May 17 23:37:12 CST 2018, time=2018-05-17, status=1, ipAttribution=)]
    2020-10-10 1871f037efm

    我要下载

    0

  2. [GetPortalCommentsPageByObjectIdResponse(id=890958, encodeId=006b890958fd, content=我要下载, beContent=null, objectType=guider, channel=null, level=null, likeNumber=87, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=dc0c2071567, createdName=1871f037efm, createdTime=Sat Oct 10 09:23:20 CST 2020, time=2020-10-10, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=316352, encodeId=2aa831635298, content=好, beContent=null, objectType=guider, channel=null, level=null, likeNumber=100, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=41962298363, createdName=121ff658m46暂无昵称, createdTime=Fri May 18 15:42:59 CST 2018, time=2018-05-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=316134, encodeId=823531613478, content=谢谢分享学习, beContent=null, objectType=guider, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/Q3auHgzwzM4o2XVpJ6449yqDsjibydI5HnJ8MibGxNn4HZiaZib0bdfibbwoz3KQrIyN9AGxq36ZlZRNicYlPfOOWMtwgsajY6mGNFiaPclFdowjD0/0, createdBy=97bd1338592, createdName=清风拂面, createdTime=Thu May 17 23:37:12 CST 2018, time=2018-05-17, status=1, ipAttribution=)]
    2018-05-18 121ff658m46暂无昵称

    好

    0

  3. [GetPortalCommentsPageByObjectIdResponse(id=890958, encodeId=006b890958fd, content=我要下载, beContent=null, objectType=guider, channel=null, level=null, likeNumber=87, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=dc0c2071567, createdName=1871f037efm, createdTime=Sat Oct 10 09:23:20 CST 2020, time=2020-10-10, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=316352, encodeId=2aa831635298, content=好, beContent=null, objectType=guider, channel=null, level=null, likeNumber=100, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=41962298363, createdName=121ff658m46暂无昵称, createdTime=Fri May 18 15:42:59 CST 2018, time=2018-05-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=316134, encodeId=823531613478, content=谢谢分享学习, beContent=null, objectType=guider, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/Q3auHgzwzM4o2XVpJ6449yqDsjibydI5HnJ8MibGxNn4HZiaZib0bdfibbwoz3KQrIyN9AGxq36ZlZRNicYlPfOOWMtwgsajY6mGNFiaPclFdowjD0/0, createdBy=97bd1338592, createdName=清风拂面, createdTime=Thu May 17 23:37:12 CST 2018, time=2018-05-17, status=1, ipAttribution=)]
    2018-05-17 清风拂面

    谢谢分享学习

    0

相关指南

2015 AGA 免疫抑制治疗中乙肝病毒再激活防治指南

美国胃肠病协会(AGA,American Gastroenterological Association) · 2014-10-31